icrf 193 has been researched along with Abnormalities, Autosome in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clarke, DJ; Giménez-Abián, JF; Lane, AB | 1 |
| Clarke, DJ; Giménez-Abián, JF | 1 |
| Bestor, TH; Damelin, M; Sodja, VB; Sun, YE | 1 |
| Kranendonk, M; Laires, A; Maralhas, A; Martins, C; Monteiro, A; Rodrigues, AS; Rueff, J | 1 |
| Kaufmann, WK | 1 |
| Cao, L; Deng, CX; Tominaga, Y; Wang, A; Wang, RH; Wang, X | 1 |
| Clarke, DJ; Downes, CS; Giménez-Abián, JF; Johnson, RT; Mullinger, AM | 1 |
| Andoh, T; Aratani, Y; Koyama, H | 1 |
| Ikushima, T; Ishii, Y; Shima, Y | 1 |
| Cortés, F; Domínguez, I; Mateos, S; Pastor, N | 1 |
| Kamiguchi, Y; Tateno, H | 1 |
| Ikushima, T; Ishii, Y | 1 |
12 other study(ies) available for icrf 193 and Abnormalities, Autosome
| Article | Year |
|---|---|
Analyzing Mitotic Chromosome Structural Defects After Topoisomerase II Inhibition or Mutation.
Topics: Cell Cycle Checkpoints; Chromosome Aberrations; Chromosomes, Human; Diketopiperazines; DNA Topoisomerases, Type II; HEK293 Cells; HeLa Cells; Humans; Mitosis; Mutation; Phenotype; Piperazines; Poly-ADP-Ribose Binding Proteins; Topoisomerase II Inhibitors | 2018 |
Cytological analysis of chromosome structural defects that result from topoisomerase II dysfunction.
Topics: Cell Cycle; Chromosome Aberrations; Chromosomes; Diketopiperazines; DNA Topoisomerases, Type II; Enzyme Inhibitors; HeLa Cells; Humans; Piperazines; Silver Staining; Spindle Apparatus; Topoisomerase II Inhibitors | 2009 |
Decatenation checkpoint deficiency in stem and progenitor cells.
Topics: Animals; Cell Differentiation; Cell Division; Cell Line; Chromosome Aberrations; Diketopiperazines; Etoposide; Genes, cdc; Hematopoietic Stem Cells; Humans; Mice; Neurons; Piperazines; Stem Cells; Time Factors | 2005 |
Genotoxicity and endoreduplication inducing activity of the food flavouring eugenol.
Topics: Animals; Biotransformation; Cells, Cultured; Chromosome Aberrations; Cricetinae; Diketopiperazines; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Eugenol; Flavoring Agents; Mutagenicity Tests; Piperazines | 2006 |
Dangerous entanglements.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Transformation, Neoplastic; Chromosome Aberrations; Diketopiperazines; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; G2 Phase; Genomic Instability; Humans; Piperazines; Regenerative Medicine; Stem Cell Transplantation; Stem Cells; Topoisomerase II Inhibitors | 2006 |
Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Chromosome Aberrations; Diketopiperazines; DNA Damage; Gene Expression Regulation, Neoplastic; Genistein; Mice; Mitosis; Mutation; Piperazines; Polyploidy; Topoisomerase II Inhibitors | 2007 |
A postprophase topoisomerase II-dependent chromatid core separation step in the formation of metaphase chromosomes.
Topics: Animals; Cell Line, Transformed; Chromatids; Chromosome Aberrations; Chromosome Disorders; Chromosomes; Diketopiperazines; DNA Topoisomerases, Type II; Enzyme Inhibitors; Fibroblasts; Metaphase; Mitosis; Muntjacs; Piperazines; Prophase; Silver Staining; Time Factors; Topoisomerase II Inhibitors | 1995 |
Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells.
Topics: Adenine Phosphoribosyltransferase; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; CHO Cells; Chromosome Aberrations; Cricetinae; Diketopiperazines; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Mutagenesis; Mutagenicity Tests; Nucleic Acid Heteroduplexes; Piperazines; Recombination, Genetic; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transfection | 1996 |
Effects of an inhibitor of topoisomerase II, ICRF-193 on the formation of ultraviolet-induced chromosomal aberrations.
Topics: Animals; Cells, Cultured; Chromatids; Chromosome Aberrations; Chromosomes; Cricetinae; Cricetulus; Diketopiperazines; DNA Repair; Enzyme Inhibitors; Interphase; Piperazines; Topoisomerase II Inhibitors; Ultraviolet Rays | 1998 |
Testing the SCE mechanism with non-poisoning topoisomerase II inhibitors.
Topics: Animals; Bufanolides; CHO Cells; Chromosome Aberrations; Cricetinae; Diketopiperazines; DNA Repair; Enzyme Inhibitors; Models, Genetic; Mutation; Piperazines; Recombination, Genetic; Sister Chromatid Exchange; Topoisomerase II Inhibitors | 2001 |
Abnormal chromosome migration and chromosome aberrations in mouse oocytes during meiosis II in the presence of topoisomerase II inhibitor ICRF-193.
Topics: Animals; Chromosome Aberrations; Diketopiperazines; DNA Replication; Enzyme Inhibitors; Karyotyping; Meiosis; Mice; Oocytes; Piperazines; Topoisomerase II Inhibitors | 2002 |
Post-treatment effects of DNA topoisomerase inhibitors on UVB- and X-ray-induced chromosomal aberration formations.
Topics: Animals; Cell Cycle; Cell Line; Chromosome Aberrations; Chromosome Breakage; Chromosome Deletion; Diketopiperazines; Humans; Lymphocytes; Male; Nogalamycin; Nucleic Acid Synthesis Inhibitors; Piperazines; Ring Chromosomes; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Ultraviolet Rays | 2002 |